FGHQ.F Stock Overview
A contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Frontage Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.10 |
| 52 Week High | HK$0.16 |
| 52 Week Low | HK$0.10 |
| Beta | 0.84 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| FGHQ.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 2.2% |
| 1Y | n/a | 2.9% | 31.7% |
Return vs Industry: Insufficient data to determine how FGHQ.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how FGHQ.F performed against the US Market.
Price Volatility
| FGHQ.F volatility | |
|---|---|
| FGHQ.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FGHQ.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FGHQ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1,657 | Abdul Mutlib | www.frontagelab.com |
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis.
Frontage Holdings Corporation Fundamentals Summary
| FGHQ.F fundamental statistics | |
|---|---|
| Market cap | US$158.39m |
| Earnings (TTM) | US$6.10m |
| Revenue (TTM) | US$259.97m |
26.0x
P/E Ratio0.6x
P/S RatioIs FGHQ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FGHQ.F income statement (TTM) | |
|---|---|
| Revenue | US$259.97m |
| Cost of Revenue | US$185.73m |
| Gross Profit | US$74.25m |
| Other Expenses | US$68.15m |
| Earnings | US$6.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.003 |
| Gross Margin | 28.56% |
| Net Profit Margin | 2.35% |
| Debt/Equity Ratio | 28.5% |
How did FGHQ.F perform over the long term?
See historical performance and comparison